Search results
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Saturday 11 April 2026, 11.00am - 1.00pm - In-person - Come and join Valerie and the group for our first meeting of 2026 when we return to the Festival Theatre, Edinburgh to hear from guest speaker Chloe Brotherton, PhD Student working with Dr Roly Megaw.
Wednesday 6 May 2026, 7.00pm - 8.00pm - via Zoom - Please come and join Anna & Ellie for our latest meeting where we are delighted to welcome our guest speakers David Sikharulidze, founder & CEO and Martin Wingfield, CMO from Mavis Technologies.
Have you ever been tempted to take part in the TCS London Marathon? In 2022 the TCS London Marathon raised £58.3 million for charity so it’s a vital source of income.
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Whether you are a professional looking for practical information for yourself, or practical or emotional support for your clients, online, by phone or face-to-face, we're here to help. All of our services are free to access and offered in a range of accessible formats.
We are delighted to welcome Kathy Evans as our new Chair of Trustees.
We sat down to discuss what our volunteers got up to on Retina UK day.
Are you a parent or carer of a child or young person living with an inherited retinal dystrophy?
